𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High-resolution genomic and expression analyses of copy number alterations in breast tumors

✍ Scribed by Peter M. Haverty; Jane Fridlyand; Li Li; Gad Getz; Rameen Beroukhim; Scott Lohr; Thomas D. Wu; Guy Cavet; Zemin Zhang; John Chant


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
1018 KB
Volume
47
Category
Article
ISSN
1045-2257

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Analysis of recurrent DNA amplification can lead to the identification of cancer driver genes, but this process is often hampered by the low resolution of existing copy number analysis platforms. Fifty‐one breast tumors were profiled for copy number alterations (CNAs) with the high‐resolution Affymetrix 500K SNP array. These tumors were also expression‐profiled and surveyed for mutations in selected genes commonly mutated in breast cancer (TP53, CDKN2A, ERBB2, KRAS, PIK3CA, PTEN). Combined analysis of common CNAs and mutations revealed putative associations between features. Analysis of both the prevalence and amplitude of CNAs defined regions of recurrent alteration. Compared with previous array comparative genomic hybridization studies, our analysis provided boundaries for frequently altered regions that were approximately one‐fourth the size, greatly reducing the number of potential alteration‐driving genes. Expression data from matched tumor samples were used to further interrogate the functional relevance of genes located in recurrent amplicons. Although our data support the importance of some known driver genes such as ERBB2, refined amplicon boundaries at other locations, such as 8p11‐12 and 11q13.5‐q14.2, greatly reduce the number of potential driver genes and indicate alternatives to commonly suggested driver genes in some cases. For example, the previously reported recurrent amplification at 17q23.2 is reduced to a 249 kb minimal region containing the putative driver RPS6KB1 as well as the putative oncogenic microRNA mir‐21. High‐resolution copy number analysis provides refined insight into many breast cancer amplicons and their relationships to gene expression, point mutations and breast cancer subtype classifications. This article contains Supplementary Material available at http://www.interscience.wiley.com/jpages/1045‐2257/suppmat. © 2008 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Genomic copy number alterations as predi
✍ Ki-Tae Hwang; Wonshik Han; Jihyoung Cho; Jong Won Lee; Eunyoung Ko; Eun Kyu Kim; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 462 KB

## Abstract We tried to establish models that predict systemic recurrence in breast cancer by selecting marker clones with DNA copy number alterations (CNAs) using an array comparative genomic hybridization (CGH). Array CGH containing 4,044 human bacterial artificial chromosome clones was used to a

High-resolution copy number arrays in ca
✍ Kylie L. Gorringe; Ian G. Campbell 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB

## Abstract High‐resolution techniques for analysis of genome copy number (CN) enable the analysis of complex cancer somatic genetics. However, the analysis of these data is difficult, and failure to consider a number of issues in depth may result in false leads or unnecessary rejection of true pos

Overlapping high-resolution copy number
✍ Chian-Feng Chen; En-Chi Hsu; Kuen-Tyng Lin; Pang-Hsien Tu; Hung-Wei Chang; Chin- 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 605 KB

Recurrent cancer genome aberrations are indicators of residing crucial cancer genes. Although recent advances in genomic technologies have led to a global view of cancer genome aberrations, the identification of target genes and biomarkers from the aberrant loci remains difficult. To facilitate sear

DNA copy number alterations and expressi
✍ Wonshik Han; Eun-Mi Jung; Jihyoung Cho; Jong Won Lee; Ki-Tae Hwang; Song-Ju Yang 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 332 KB

## Abstract Triple‐negative breast cancer (TNBC) is defined by a lack of expression of estrogen, progesterone, and HER2 receptors, and genetically most of them fall into the basal subgroup of breast cancer. The important issue of TNBC is poorer clinical outcome and absence of effective targeted the